Patent intelligence ยท AT
AT E216995
KRISTALLINE MUPIROCINPOLYMORPHE
KRISTALLINE MUPIROCINPOLYMORPHE
Patent details โ AT E216995
- Jurisdiction
- AT
- Status
- expired
- Grant date
- May 15, 2002
- Expiration
- May 10, 2022
- Applicant
- BEECHAM GROUP PLC [GB]
- CPC classes
- A61K 31/ 35 A I, A61K 31/ 351 A I, A61K31/35, A61P 31/ 04 A I
Quick answer
AT E216995 (KRISTALLINE MUPIROCINPOLYMORPHE) is held by BEECHAM GROUP PLC [GB]. Status: expired. Granted May 15, 2002. Expires May 10, 2022 (0 years remaining) โ relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BEECHAM GROUP PLC [GB]
- Grant date
- Expiration
- Claims
- โ
- CPC classes
- A61K 31/ 35 A I, A61K 31/ 351 A I, A61K31/35, A61P 31/ 04 A I, A61P/3104
More from BEECHAM GROUP PLC [GB]
Related pharmaceutical patents in our USPTO index.
-
SA 92120308
ุชุฑููุจุฉ ููุงุณุชุฎุฏุงู ุงูู ูุถุนู topical composition
expired -
AT E269330
CHEMISCHE VERBINDUNGEN
expired -
EP 1425277
HARNSTOFF-DERIVATE ALS VANILLOID-REZEPTOR-ANTAGONISTEN FรR DIE SCHMERZBEHANDLUNG
expired -
SA 91110341
ู ุณุชุญุถุฑ ู ูุถุนู ูุนูุงุฌ ุงูุนุฏูู ุจููุฑูุณ ุงูุญูุง (ุงูููุจุงุก) Herpesvirus
expired -
HU P0302480
PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
expired -
AT E245157
3,9-DIAZABICYCLO-(3.3.1)-NONANYLDERIVATE, VERFAHREN UND INTERMEDIATE FรR IHRE DARSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
expired -
HK 1004528
Dentifrice compositions
expired -
HU P0204410
PYRIMIDINE-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE
expired
Frequently asked questions
What is US patent E216995?
AT E216995 (KRISTALLINE MUPIROCINPOLYMORPHE) is held by BEECHAM GROUP PLC [GB]. Status: expired. Granted May 15, 2002. Expires May 10, 2022 (0 years remaining) โ relevant for patent-cliff and LOE planning.
Who owns AT E216995?
BEECHAM GROUP PLC [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AT E216995 expire?
Our index shows an expiration date of May 10, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.